A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

Go Back to All Clinical Trials

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

Brief description of study

This study is being done to see if the overall survival or improvement of the recurrence-free survival from cervical cancer can be increased by adding an immunotherapy drug (MK-3475, pembrolizumab) plus chemotherapy before starting the usual combination of chemotherapy and radiation.

Clinical Study Identifier: s25-01580

ClinicalTrials.gov Identifier: NCT07061977

Principal Investigator: Leslie R Boyd.

Other Investigators: Kent Chan, Cindy Corbo, Sarah Saerohm Lee, Marina Stasenko, Fabia Brisard Pierrot, Alexander A Hindenburg, Christina Grace Wilson, Fauzia Shaikh, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Whitfield B. Growdon, Marilyn Huang, Anastasiya Apanasyuk, Victoria Helen Dowd, Kelly A Levine, Rupal Bhana, Thomas B. Daniels, Edward A Jimenez, Erin Annette Reese, Sabrina Machado, Bhavana Pothuri, Joseph Kiho Kim, Kathleen M Lutz.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies